We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+7.52%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.33B
AUM Growth
+$713M
Cap. Flow
+$1.03B
Cap. Flow %
77.19%
Top 10 Hldgs %
46.07%
Holding
196
New
82
Increased
39
Reduced
17
Closed
45

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$20M
2
XLRN
Acceleron Pharma
XLRN
+$18.6M
3
TARA icon
Protara Therapeutics
TARA
+$12.9M
4
BTAI icon
BioXcel Therapeutics
BTAI
+$12M
5
VSTM icon
Verastem
VSTM
+$11M

Top Sells

Rank Stock Value
1
APTO
Aptose Biosciences, Inc.
APTO
+$5.72M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$4.63M
3
TGTX icon
TG Therapeutics
TGTX
+$3.51M
4
KALA icon
KALA BIO
KALA
+$3.39M
5
ARQL
Arqule Inc
ARQL
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 19.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
26
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
$13.1M 0.98%
+120,300
New +$13.9M
BHVN
27
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$11.9M 0.9%
350,000
+150,000
+75% +$6.86M
MRTX
28
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11.4M 0.86%
148,900
+100,000
+204% +$8.97M
ABBV icon
29
CALL
AbbVie
ABBV
$443B
$11.4M 0.86%
+150,000
New +$12.8M
ICPT
30
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$10.8M 0.81%
172,100
-582,800
-77% -$52.4M
KPTI icon
31
PUT
Karyopharm Therapeutics
KPTI
$43.5M
$10.6M 0.8%
36,787
+23,447
+176% +$6.47M
TARA icon
32
Protara Therapeutics
TARA
$220M
$10.4M 0.78%
450,772
+442,363
+5,261% +$12.9M
ADVM
33
CALL
DELISTED
Adverum Biotechnologies
ADVM
$10.2M 0.77%
22,440
-16,650
-43% -$1.94M
ACAD icon
34
PUT
Acadia Pharmaceuticals
ACAD
$4.43B
$10.1M 0.76%
240,000
+100,000
+71% +$4.12M
SRPT icon
35
CALL
Sarepta Therapeutics
SRPT
$1.57B
$10M 0.75%
102,600
– –
KDNY
36
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$9.97M 0.75%
727,600
+359,894
+98% +$4.26M
ARGX icon
37
CALL
argenx
ARGX
$53.4B
$9.88M 0.74%
+75,000
New +$11M
AXSM icon
38
PUT
Axsome Therapeutics
AXSM
$11.2B
$8.82M 0.66%
150,000
+122,100
+438% +$9.95M
ARGX icon
39
argenx
ARGX
$53.4B
$8.68M 0.65%
+65,856
New +$9.64M
NBIX icon
40
CALL
Neurocrine Biosciences
NBIX
$16.8B
$8.65M 0.65%
100,000
+92,800
+1,289% +$9.08M
ARDX icon
41
Ardelyx
ARDX
$1.22B
$8.31M 0.63%
1,462,234
+816,798
+127% +$5.55M
SCPH
42
DELISTED
scPharmaceuticals
SCPH
$7.95M 0.6%
+1,073,647
New +$7.79M
OCUL icon
43
Ocular Therapeutix
OCUL
$1.79B
$7.72M 0.58%
1,558,936
+1,001,277
+180% +$4.94M
CRSP icon
44
PUT
CRISPR Therapeutics
CRSP
$4.73B
$7.6M 0.57%
179,100
+55,400
+45% +$2.86M
CHMA
45
DELISTED
Chiasma, Inc. Common Stock
CHMA
$7.58M 0.57%
2,075,492
+972,195
+88% +$4.31M
KURA icon
46
Kura Oncology
KURA
$800M
$7.56M 0.57%
+759,803
New +$8.7M
TPST icon
47
PUT
Tempest Therapeutics
TPST
$13.7M
$7.41M 0.56%
+7,199
New +$10.5M
TVRD
48
Tvardi Therapeutics
TVRD
$19.7M
$7.29M 0.55%
+15,338
New +$8.33M
KALV
49
DELISTED
KalVista Pharmaceuticals
KALV
$7.24M 0.54%
946,605
+734,185
+346% +$9.91M
KYNB
50
CALL
Kyntra Bio
KYNB
$27.2M
$6.95M 0.52%
+8,000
New +$7.95M
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Ikarian Capital held 196 positions worth $1.33B, up 115% from $617M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Ikarian Capital deployed $1.03B of net new capital in Q1 2020, opening 82 new positions and adding to 39 existing holdings. Its largest new stake was Zogenix, Inc.: 549,459 shares worth $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 16% a quarter earlier.

On the sell side, the largest reduction was Aurinia Pharmaceuticals, an estimated $4.63M trimmed.

  • Ikarian Capital's largest Q1 2020 buy was Zogenix, Inc.: 549,459 shares worth $13.6M.
  • Ikarian Capital added most to Protara Therapeutics in Q1 2020, an estimated $12.9M increase.
  • Ikarian Capital's biggest Q1 2020 reduction was Aurinia Pharmaceuticals, cutting an estimated $4.63M.
  • Ikarian Capital fully exited Aptose Biosciences, Inc. in Q1 2020, selling an estimated $5.72M.
  • Ikarian Capital's ten largest holdings make up 46% of its $1.33B portfolio in Q1 2020.
  • Ikarian Capital opened 82 new positions and closed 45 in Q1 2020.
  • Ikarian Capital's portfolio value rose 115% quarter-over-quarter to $1.33B.

Based on Ikarian Capital's 13F filing for Q1 2020, filed 15 May 2020.